Bicara Therapeutics reported net income of -$55.76M for the quarter ended Jun 2026. This income statement covers 12 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.58M | 0.64M | 0.64M | 1.02M | 10.90M | 16.81M | 54.53M | 54.56M | 54.61M | 56.60M | 65.55M | 65.93M |
| Operating items | ||||||||||||
| Research & DevelopmentR&D | 6.90M | 10.50M | 12.00M | 15.80M | 15.90M | 19.90M | 34.30M | 24.80M | 33.00M | 33.00M | 47.50M | 45.77M |
| Selling, General & AdministrativeSG&A | 2.59M | 3.12M | 3.34M | 3.91M | 4.76M | 6.75M | 7.46M | 7.22M | 7.70M | 8.13M | 12.74M | 14.18M |
| Other Operating ExpensesOther Opex | 0.04M | 0.06M | 0.03M | 0.04M | -0.04M | -0.02M | 0.03M | -0.00M | -0.03M | -0.01M | ||
| Operating ExpensesOpex | 9.53M | 13.69M | 15.37M | 19.75M | 20.63M | 26.64M | 41.79M | 32.02M | 40.68M | 41.12M | 60.24M | 59.95M |
| Operating IncomeOp. Inc | -9.53M | -13.69M | -15.37M | -19.75M | -20.63M | -26.64M | -41.79M | -32.02M | -40.68M | -41.12M | -60.24M | -59.95M |
| EBIT | -9.53M | -13.69M | -15.37M | -19.75M | -20.63M | -26.64M | -41.79M | -32.02M | -40.68M | -41.12M | -60.24M | -59.95M |
| Non-operating items | ||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | 1.30M | 2.87M | 2.70M | 3.15M | 5.87M | 5.01M | 4.68M | 4.39M | 3.79M | 4.08M | 4.58M |
| Non Operating IncomeNon Op. Inc. | -13.31M | 1.25M | 2.87M | 2.70M | 3.15M | 5.87M | 5.01M | 4.68M | 4.39M | 3.79M | 4.08M | 4.58M |
| Net income details | ||||||||||||
| EBT | -22.84M | -12.44M | -12.51M | -17.05M | -17.48M | -20.77M | -36.77M | -27.34M | -36.29M | -37.33M | -56.16M | -55.38M |
| Tax ProvisionsTaxes | 0.01M | 0.00M | 0.19M | 0.07M | 0.05M | 0.04M | 0.05M | 0.05M | 0.06M | |||
| Profit After TaxPAT | -22.84M | -12.44M | -12.51M | -17.05M | -17.48M | -20.96M | -36.85M | -27.39M | -36.47M | -37.25M | -56.21M | -55.76M |
| Income from Continuing OperationsIncome (Continuing) | -22.84M | -12.44M | -12.51M | -17.05M | -17.48M | -20.96M | -36.85M | -27.39M | -36.33M | -37.39M | -56.21M | -55.44M |
| Consolidated Net IncomeConsol Net Inc. | -22.84M | -12.44M | -12.51M | -17.05M | -17.48M | -20.96M | -36.85M | -27.39M | -36.33M | -37.39M | -56.21M | -55.44M |
| Income towards Parent CompanyParent Net Inc | -22.84M | -12.44M | -12.51M | -17.05M | -17.48M | -20.96M | -36.85M | -27.39M | -36.33M | -37.39M | -56.21M | -55.44M |
| Net Income towards Common StockholdersNet Income | -22.84M | -12.44M | -12.51M | -17.05M | -17.48M | -20.96M | -36.85M | -27.39M | -36.33M | -37.39M | -56.21M | -55.44M |
| Additional items | ||||||||||||
| EPS (Basic) | -38.23 | -21.44 | -18.94 | -19.01 | -1.60 | -1.25 | -0.68 | -0.50 | -0.67 | -0.68 | -0.93 | -0.82 |
| EPS (Diluted) | -38.23 | -21.44 | -18.94 | -19.01 | -1.60 | -1.25 | -0.68 | -0.50 | -0.67 | -0.68 | -0.93 | -0.82 |
| Shares Outstanding | 0.60M | 0.58M | 0.66M | 0.90M | 10.90M | 16.81M | 54.46M | 54.54M | 54.56M | 54.68M | 60.72M | 67.93M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.60M | 0.58M | 0.66M | 0.90M | 10.90M | 16.81M | 54.46M | 54.54M | 54.56M | 54.68M | 60.72M | 67.93M |
| EBITDA | -9.53M | -13.69M | -15.37M | -19.75M | -20.63M | -26.64M | -41.79M | -32.02M | -40.68M | -41.12M | -60.24M | -59.95M |
| Tax Rate | -0.04 | -0.01 | -0.90 | -0.20 | -0.19 | -0.11 | -0.14 | -0.09 | -0.11 |